Bristol-Myers Squibb Company (BMY) Position Increased by Hartland & Co. LLC

Hartland & Co. LLC raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 8.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 58,241 shares of the biopharmaceutical company’s stock after purchasing an additional 4,748 shares during the period. Hartland & Co. LLC’s holdings in Bristol-Myers Squibb were worth $3,246,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of BMY. Waldron LP purchased a new stake in shares of Bristol-Myers Squibb in the first quarter valued at $475,000. Tufton Capital Management lifted its position in Bristol-Myers Squibb by 2.2% during the first quarter. Tufton Capital Management now owns 137,374 shares of the biopharmaceutical company’s stock worth $7,470,000 after buying an additional 3,007 shares during the period. Greenleaf Trust lifted its position in Bristol-Myers Squibb by 8.4% during the first quarter. Greenleaf Trust now owns 9,569 shares of the biopharmaceutical company’s stock worth $520,000 after buying an additional 742 shares during the period. Oxbow Advisors LLC lifted its position in Bristol-Myers Squibb by 2.9% during the first quarter. Oxbow Advisors LLC now owns 20,716 shares of the biopharmaceutical company’s stock worth $1,127,000 after buying an additional 581 shares during the period. Finally, Rockefeller Financial Services Inc. lifted its position in Bristol-Myers Squibb by 0.7% during the first quarter. Rockefeller Financial Services Inc. now owns 25,200 shares of the biopharmaceutical company’s stock worth $1,371,000 after buying an additional 176 shares during the period. 69.51% of the stock is currently owned by institutional investors.

BMY has been the topic of a number of research reports. Credit Suisse Group AG set a $58.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday, August 16th. BMO Capital Markets restated an “underperform” rating and issued a $47.00 price objective (down from $51.00) on shares of Bristol-Myers Squibb in a report on Wednesday, July 26th. Leerink Swann lowered their target price on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research note on Friday, July 28th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, Cowen and Company restated a “hold” rating and set a $65.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $64.93.

TRADEMARK VIOLATION WARNING: This article was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://weekherald.com/2017/11/15/hartland-co-llc-acquires-4748-shares-of-bristol-myers-squibb-company-bmy.html.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $61.25 on Wednesday. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10. The firm has a market capitalization of $100,250.00, a PE ratio of 20.56, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period in the prior year, the firm earned $0.77 EPS. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. sell-side analysts expect that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were paid a dividend of $0.39 per share. The ex-dividend date was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply